(fer-u-mox-y-tole) ,


(trade name)


Therapeutic: antianemics
Pharmacologic: iron supplements
Pregnancy Category: C


Treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD).


Consists of a superparamagnetic iron oxide coated with a carbohydrate shell; when the iron-carbohydrate complex enters the reticuloendothelial system (RES), iron is released from the iron-carbohydrate complex within macrophages. This iron can either enter the intracellular storage iron pool or be transferred to erythroid precursor cells for incorporation into hemoglobin.

Therapeutic effects

Improvement in anemia in patients with chronic kidney disease.


Absorption: IV administration results in complete bioavailability of iron-carboydrate complex, however iron is not liberated until incorporation into RES.
Distribution: Taken up by RES.
Metabolism and Excretion: Iron can either become part of intracellular ferritin or be transferred to erythroid precursor cells.
Half-life: 15 hr.

Time/action profile (effect on anemia)

IVunknownunknownup to 1 mo


Contraindicated in: Hypersensitivity;Evidence of iron overload;Anemia not due to iron deficiency; Lactation: Avoid use.
Use Cautiously in: MRI; Geriatric: Consider age-related ↓ in hepatic, renal, or cardiac function, and concurrent diseases or other drug therapy; dose cautiously; Obstetric: Use only if potential benefit justifies potential risk to the fetus; Pediatric: Safety and effectiveness not established.

Adverse Reactions/Side Effects

Central nervous system

  • dizziness (most frequent)


  • hypotension (life-threatening)
  • hypertension
  • peripheral edema


  • constipation (most frequent)
  • diarrhea (most frequent)
  • nausea (most frequent)


  • iron overload


  • hypersensitivity reactions including anaphylaxis and anaphylactoid reactions (life-threatening)


Drug-Drug interaction

May ↓ absorption of concurrently administered oral iron preparations.


Intravenous (Adults ≥ 18yr) 510 mg initially, followed by a second 510-mg IV injection 3 to 8 days later. Course may be repeated after 1 mo.


Aqueous colloid for intravenous injection: 510-mg elemental iron/17 mL (30 mg/mL) vials

Nursing implications

Nursing assessment

  • Assess nutritional status and dietary history to determine need for patient teaching.
  • Assess bowel function for constipation or diarrhea. Notify health care professional and use appropriate measures should these occur.
  • Monitor BP frequently following administration until stable. May cause hypotension. For patients receiving hemodialysis, administer ferumoxytol once the BP is stable and at least 1 hr of hemodialysis has been completed.
  • Observe patient for signs and symptoms of anaphylaxis (cardiac/cardiorespiratory arrest, clinically significant hypotension, syncope, unresponsiveness, rash, pruritus, urticaria, laryngeal edema, wheezing) for at least 30 min following injection. May occur with first or subsequent doses. Notify health care professional immediately if these occur. Keep epinephrine and resuscitation equipment close by in the event of an anaphylactic reaction.
  • Conduct MRI studies prior to administration. Alteration of MRI studies may persist for up to 3 mo following a dose; if imaging is required within 3 mo after administration, use T1- or proton density-weighted MR pulse sequences to decrease effects; MRI using T2-weighted pulse sequences should not be performed earlier than 4 weeks after administration; maximum alteration of vascular MRI is evident for 1–2 days after dose. Ferumoxytol does not interfere with x-ray, computed tomography (CT), or positron emission tomography (PET), single photon emission computed tomography (SPECT), ultrasound, or nuclear imaging.
  • Lab Test Considerations: Monitor hemoglobin, ferritin, iron and transferrin saturation prior to and at least 1 mo following second dose and regularly thereafter. Iron and transferrin bound iron may be overestimated within first 24 hr by measuring iron in the Fereheme complex.

Potential Nursing Diagnoses

Activity intolerance


  • Intermittent Infusion: Administer undiluted. Do not administer solutions that are discolored or contain particulate matter. Solution may be stored at room temperature.
  • Rate: Administer at a rate of 1 mL/sec (30 mg/sec).

Patient/Family Teaching

  • Explain purpose of iron therapy to patient.
  • Advise patients to avoid MRI studies during and for 3 mo following ferumoxytol therapy.
  • May cause dizziness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
  • Advise patient to report signs and symptoms of hypersensitivity reactions (rash, itching, dizziness, swelling, and breathing problems) to health care professional immediately.

Evaluation/Desired Outcomes

  • Improvement in iron deficiency anemia.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
Ferumoxytol contrast-enhanced magnetic resonance venography (MRV) (2), demonstrated a large infrahepatic caval thrombus extending from the IVC filter down into the bilateral common, external and internal iliac veins and nonocclusive thrombus within the transplant renal vein (Fig.
Several IV iron preparations are available in the United States, including ferric carboxymaltose, iron sucrose, sodium ferric gluconate, ferumoxytol, and iron dextran.
The ASH poster presentation focused on the durability of the improvements in several patient reported outcomes, or PRO, measures in patients with iron deficiency anemia, or IDA, following a single course of ferumoxytol over a 6-month extension study period.
Treated patients received IV ferumoxytol 510 mg every week for two doses or iron sucrose 200 mg every week for five doses.
They are low-molecular-weight iron dextran (1 hr), ferumoxytol (15 mins), ferric carboxymaltose (15 mins) and iron isomaltoside (15 mins).
The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: A pilot study.
MSCs were labeled with Ferumoxytol (Southeast University, Nanjing, China), as previously described [15].
Chapelin et al., "Ferumoxytol: a new, clinically applicable label for stem-cell tracking in arthritic joints with MRI," Nanomedicine, vol.
Henry et al., "Magnetic targeting of cardiosphere-derived stem cells with ferumoxytol nanoparticles for treating rats with myocardial infarction," Biomaterials, vol.
Muldoon et al., "Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs.
The company said the increase in revenue is primarily related to record annual net sales of Makena and the recognition of a full year of service revenues from CBR, partially offset by the recognition of USD52.3m of collaboration revenue in 2015 related to the termination of the company's ex-US ferumoxytol marketing agreement.